KPV is one of the smallest peptides discussed in the therapeutic peptide space — just three amino acids — yet its anti-inflammatory effects in preclinical models of intestinal inflammation are among the most impressive in the peptide literature. This article examines what the research shows, where the evidence stands, and what that means for gut-related conditions.
At a Glance
| Property | Detail |
|---|---|
| Type | Synthetic fragment of endogenous peptide |
| Amino acid count | 3 |
| Primary mechanism | NF-kB inhibition, anti-inflammatory cytokine modulation |
| Evidence level | Animal studies; limited clinical observation |
| Regulatory status | Not approved; FDA-flagged compounding safety risk |
| Route of administration | Oral, SC injection, rectal (compounded) |
| Anti-doping (WADA 2026) | Not named; as a non-approved substance it falls under S0 (prohibited at all times) |
What Is KPV?
KPV is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH), consisting of the amino acids lysine-proline-valine. Alpha-MSH is a 13-amino-acid neuropeptide produced by the pituitary gland and by various immune cells. It is best known for its role in skin pigmentation, but alpha-MSH is also a potent endogenous anti-inflammatory molecule.

Research in the 1990s and 2000s established that the anti-inflammatory activity of alpha-MSH resides primarily in its C-terminal tripeptide — KPV. This was a significant finding because it demonstrated that the melanogenic (pigmentation) effects and the anti-inflammatory effects of alpha-MSH are mediated by different regions of the molecule. KPV retains the anti-inflammatory activity without the pigmentation effects.
This separation of activities makes KPV clinically attractive. Alpha-MSH itself would be problematic as a therapeutic agent because of its pigmentation effects. KPV provides the anti-inflammatory benefits without this limitation.
Mechanism of Action
Primary Pathways
- NF-kB Inhibition: The best-characterized mechanism of KPV is its inhibition of nuclear factor kappa B (NF-kB), the master transcription factor that drives inflammatory gene expression. KPV enters cells and directly interferes with the nuclear translocation of NF-kB, reducing the transcription of pro-inflammatory cytokines including TNF-alpha, IL-1beta, IL-6, and IL-8. This is a direct intracellular action, not a receptor-mediated effect.
- Inflammatory Cytokine Suppression: Downstream of NF-kB inhibition, KPV reduces the production of multiple pro-inflammatory mediators. In colitis models, KPV has been shown to reduce mucosal levels of TNF-alpha, IL-1beta, and myeloperoxidase (a marker of neutrophil infiltration) by 50-70%.
- Immune Cell Modulation: KPV modulates the behavior of several immune cell types. It reduces neutrophil infiltration into inflamed tissues, modulates macrophage activation, and appears to influence the balance between pro-inflammatory and regulatory immune responses in the gut mucosa.
- Intestinal Epithelial Transport: KPV has been shown to be transported across the intestinal epithelium via the peptide transporter PepT1, which is upregulated in inflamed intestinal tissue. This means that KPV may be preferentially absorbed in inflamed gut segments — a form of passive targeting that could enhance its efficacy when administered orally for intestinal inflammation.
Research Assessment
What the Evidence Shows
| Claimed Effect | Evidence Level | Key Studies | Assessment |
|---|---|---|---|
| NF-kB inhibition | In vitro, animal studies | Brzoska 2008 | Strong mechanistic data |
| Mucosal healing | Animal studies | Dalmasso 2008, Kannengiesser 2008 | Promising |
| Skin inflammation reduction | Animal studies | Luger 1999 | Preliminary |
| Antimicrobial activity | In vitro | Cutuli 2000 | Preliminary |
The preclinical data for KPV in models of inflammatory bowel disease is compelling. Dalmasso and colleagues (2008) demonstrated that oral administration of KPV significantly reduced colitis severity in the dextran sodium sulfate (DSS) mouse model — a standard experimental model for IBD. The peptide reduced clinical disease scores, histological inflammation, and pro-inflammatory cytokine levels.
The finding that KPV is transported by PepT1, and that PepT1 is upregulated in inflamed intestinal tissue, provides an elegant mechanistic explanation for why an orally administered tripeptide might have preferential activity in inflamed gut tissue.
What the Evidence Does Not Show
There are no published human clinical trials of KPV for any indication. The evidence base consists entirely of in vitro studies, animal models, and clinical observation from physicians who have incorporated KPV into their practice.
The translation from DSS-induced colitis in mice to human inflammatory bowel disease is not straightforward. DSS colitis is an acute chemical injury model, while human IBD is a chronic, relapsing condition with complex immunological underpinnings. KPV’s efficacy in one model does not guarantee efficacy in the other.
Dosing
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
| Route | Dose Range | Frequency | Duration | Basis |
|---|---|---|---|---|
| Subcutaneous | 200-500 mcg | Once daily (twice daily for about a week during a flare) | 4-8 weeks | Practice protocol (flare schedule: Anecdotal) |
| Oral capsule, gut inflammation | 500-1,000 mcg | Twice daily, empty stomach | 4-8 weeks | Anecdotal |
| Rectal (compounded suppository) | 500 mcg-1 mg | Once daily | 4-8 weeks | Not found in the practice compilations; no documented source |
Note: All dosing comes from practitioner and community protocols (basis labels as in the protocol table below). There are no human dose-finding studies for KPV. The FDA lists KPV among bulk substances that may present significant safety risks in compounding, citing immunogenicity, impurities, and little or no human safety data, and no regulator has authorised it.
Protocol Table: Dose, Route, Timing and Basis
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
One row per use case. Basis: Practice protocol (reported by at least two independent compilations) or Anecdotal (community reports only). There is no Trial row because no human study of KPV has been published.
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| General anti-inflammatory use | 200-500 mcg (Peptide DB: 200-300 mcg) | SC | Once daily | 4-8 weeks | Practice protocol (Peptide Protocol Wiki; Peptide DB) |
| Active flare | 250-500 mcg | SC | Twice daily for about 1 week, then once daily | 4-8 weeks | Anecdotal (Peptide DB) |
| Gut inflammation | 500-1,000 mcg | Oral capsule, empty stomach | Twice daily | 4-8 weeks | Anecdotal (Peptide Protocol Wiki) |
| SIBO or dysbiosis | 500 mcg | Oral | Twice daily for 2 weeks, then once daily | 4-6 weeks | Anecdotal (Peptide Protocol Wiki) |
| High-dose experimental protocol | 10-20 mg | SC | Once daily | 2-4 weeks | Anecdotal (Peptide Protocol Wiki, listed as niche and far above usual doses) |
| Combined with BPC-157 for the gut | KPV 200-500 mcg + BPC-157 250-500 mcg | SC, or both oral | Once daily | 4-8 weeks | Anecdotal (Peptide Protocol Wiki, the most reported KPV stack) |
Technique, reconstitution and storage are in the peptide injection guide.
What People Report: What Works and What Doesn’t
Sources: the aggregated community data set (Peptide Protocol Wiki, 40 reports) and the protocol and side-effect lists on Peptide DB. There are no published human case series, so all of this is self-report from a small pool.
Reported to work
- Less bloating, cramping and bowel irregularity, the main reason people take it, often noticed within the first week.
- A fast start compared with other peptides: changes reported within 3-7 days, with fuller effects after 2-4 weeks of daily use.
- Calmer inflammatory skin conditions, in some reports.
Mixed or unclear
- Oral versus injected for gut problems. The oral route has a mechanistic argument (uptake by the PepT1 transporter in inflamed gut, shown in mice), and many gut users choose it, but nobody has compared routes in people.
- Joint stiffness and “general inflammation”. Described, but vague and hard to separate from other changes people make at the same time.
- How much KPV adds when it is stacked with BPC-157, which is how most gut users take it.
Reported not to work, or disappointing
- Side effects are rarely described; the compilations list “minimal to none”. Unusual tiredness or weakness is the warning sign Peptide DB lists.
- Reports from people with diagnosed inflammatory bowel disease are anecdotal and mixed in with their standard treatment, so they say nothing about KPV on its own.
- Purity of grey-market vials and capsules is unverified, which makes both good and bad reports hard to interpret.
What a properly designed trial would need to show: a first-in-human safety and pharmacokinetic study, then a randomised, placebo-controlled trial in mild to moderate ulcerative colitis on top of standard therapy, with endoscopic and calprotectin endpoints at 8-12 weeks.
Safety and Side Effects
Known
Given the absence of formal human studies, there are no systematic human safety data for KPV, and the absence of reported adverse events is not evidence of safety. The parent molecule, alpha-MSH, has a well-characterized safety profile, and KPV as a smaller fragment would be expected to have at least as favorable a safety profile.
Theoretical Concerns
Because KPV suppresses NF-kB signaling and inflammatory responses, there is a theoretical concern about immunosuppression with prolonged use, particularly the potential for reduced defense against gastrointestinal infections. This is a concern that applies to any anti-inflammatory intervention, not uniquely to KPV, but it warrants attention in clinical practice.
Contraindications
Active gastrointestinal infection (theoretical concern — suppressing inflammation during active infection could be counterproductive). Significant immunosuppression. Pregnancy and lactation (no data).
Drug and Supplement Interactions
No formal interaction studies exist. Theoretical caution with other immunosuppressive or anti-inflammatory medications (additive immunosuppressive effects). KPV’s mechanism of action through NF-kB inhibition could theoretically interact with medications that also affect NF-kB signaling (corticosteroids, certain biologics).
Clinical Perspective
KPV is a peptide that I find mechanistically elegant and clinically interesting, but I want to be honest about where the evidence stands. We are working with strong preclinical data and clinical observation. We do not have controlled human trial data.
When I help patients make an informed decision about KPV, it is mostly in the context of gut healing protocols — particularly for inflammatory bowel disease, post-infectious irritable bowel syndrome, and gut barrier dysfunction. It is typically combined with BPC-157 peptide therapy, alongside addressing the underlying causes of gut inflammation. That combination has not been tested in controlled human trials, and with multi-component protocols it is hard to attribute any improvement specifically to KPV.
The PepT1 transport mechanism is what makes KPV particularly interesting to me from a clinical standpoint. The idea that an anti-inflammatory peptide is preferentially absorbed in inflamed intestinal tissue is exactly the kind of targeted delivery that we strive for in medicine. If this mechanism functions as demonstrated in the preclinical studies, oral KPV could deliver its anti-inflammatory effects precisely where they are needed most.
What I tell the patients I coach is that KPV has a strong mechanistic rationale and encouraging preclinical data, but that we are still waiting for the human clinical trials that would move it from “promising” to “established.” In the meantime, for people who have not responded adequately to conventional approaches, KPV is a reasonable option to discuss with a physician — provided they understand the limitations of the current evidence and that no systematic human safety data exist.

References
- Dalmasso G, et al. “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology. 2008;134(1):166-178. PMID 18061177
- Brzoska T, et al. “Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, anti-inflammatory and protective effects.” Endocr Rev. 2008;29(5):581-602. PMID 18612139
- Kannengiesser K, et al. “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.” Inflamm Bowel Dis. 2008;14(3):324-331. PMID 18092346
- Luger TA, et al. “Alpha-melanocyte-stimulating hormone as a mediator of tolerance induction.” Pathobiology. 1999;67(5-6):318-321. PMID 10725812
- Cutuli M, et al. “Antimicrobial effects of alpha-MSH peptides.” J Leukoc Biol. 2000;67(2):233-239. PMID 10670585
- Catania A, et al. “The melanocortin system in control of inflammation.” ScientificWorldJournal. 2010;10:1840-1853. PMID 20852827
Disclaimer: This peptide profile is intended for educational purposes. KPV is not approved by any regulatory agency for therapeutic use. Consult a qualified physician before pursuing any peptide therapy.
Related Reading
- All Kpv Articles
- KPV for Gut Inflammation: IBD, Colitis, and Clinical Evidence
- BPC-157 Dosage Guide: Subcutaneous, Oral, and Injection Protocols
- BPC-157 Side Effects: What the Evidence Actually Shows
- KLOW Peptide Blend: GLOW Plus KPV, Never Tested Together
- Tri-Heal Max Blend: TB-500, BPC-157 and KPV, Unstudied